Publicacións en colaboración con investigadores/as de Heidelberg University (3)

2022

  1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

2011

  1. The European Cardiac Resynchronization Therapy Survey: Comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades

    European Journal of Heart Failure, Vol. 13, Núm. 9, pp. 974-983

2010

  1. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: A randomized, multicenter study

    Transplant Infectious Disease, Vol. 12, Núm. 1, pp. 23-30